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Abstract 
Background and Aims: PFIC2 is caused by mutations in ABCB11 encoding BSEP. In most cases 
affected children need liver transplantation that is thought to be curative. We report on two 
patients who developed recurrent normal GGT cholestasis mimicking primary BSEP disease, 
after liver transplantation. Methods: PFIC2 diagnosis was made in infancy in both patients on 
absence of canalicular BSEP immunodetection and on ABCB11 mutation identification. Liver 
transplantation was performed at age 9 (girl) and 2.8 (boy) years without major complications. 
Cholestasis with normal GGT developed 17 and 4.8 years after LT, in the girl and the boy, 
respectively, during a immunosuppression reduction period. Results: Liver biopsies showed 
canalicular cholestasis, giant hepatocytes, slight lobular fibrosis, without evidence of rejection or 
biliary complications. Immunosuppression increase caused cholestasis resolution in only one 
patient. Both patients developed atrial fibrillation, and one melanonychia. The newborn of the 
girl developed transient neonatal normal GGT cholestasis. Immunofluorescence staining of 
normal human liver sections with patient’s sera, collected at time of cholestasis, and using an 
antihuman IgG antibody to detect serum antibodies, showed reactivity to a canalicular epitope, 
likely being BSEP since canalicular BSEP immunostaining was negative or faint. Conclusions: 
Allo-immune mediated BSEP dysfunction may occur after LT in PFIC2 patients leading to a 
PFIC2 like phenotype. Extrahepatic features and/or offspring transient neonatal cholestasis of 
possible immune mediated mechanism, can be associated. Increase of immunosuppressive 
regimen might be an effective therapy. 
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Introduction 
Progressive familial intrahepatic cholestasis type 2 (PFIC2) is an recessive hereditary cholestasis 
of childhood caused by mutations in ABCB11 gene, that encodes the bile salt export pump 
(BSEP) located in the canalicular membrane of the hepatocyte. PFIC2 is characterized by: the 
onset in infancy of a cholestatic jaundice with severe pruritus and failure to thrive, persistently 
normal serum gamma-glutamyl transpeptidase (GGT) activity, elevated serum bile acids, lobular 
cholestasis with a diffuse giant cell transformation of hepatocytes, absence of canalicular BSEP 
staining and profound reduction of biliary secretion of bile salts [1-4]. Progression of liver injury 
toward end stage liver disease, lack of an effective medical treatment and increased risk of 
hepatic malignancy make liver transplantation necessary, generally before adolescence, for 
patients affected by severe form [1-3]. 
So far, liver transplantation (LT) has been considered as curative for patients with inherited 
BSEP dysfunction [2,5]. However, four pediatric patients, successfully transplanted for PFIC2, 
were recently reported by two European groups to develop recurrence of cholestasis with the 
histological and biochemical features of primary BSEP deficiency [6,7]. Patients had in their sera 
anti-BSEP antibodies that caused impairment of biliary bile acid secretion. Among 20 children 
with PFIC2 who underwent LT at the pediatric liver centre of Bicêtre Hospital, two developed 
episodes of normal GGT cholestasis with features resembling to primary BSEP deficiency [2]. 
We describe here in detail their clinical, biochemical and histological characteristics that 
occurred after liver transplantation. We show evidence that these two children who were naive 
for BSEP, likely did not develop tolerance to this protein and have developed an antibody 
mediated immune response to donor BSEP after LT. 
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Patients 
Patient 1: This young baby girl presented in 1981, at age 4 months, with hepatocellular 
cholestasis, persistently normal serum GGT activity and numerous giant hepatocytes. 
Intractable pruritus, cirrhosis, and growth failure required a deceased donor LT that was 
performed at age 9 years. On this occasion, a definitive diagnosis of PFIC2 was made on the 
basis of absence of stainable canalicular BSEP on liver tissue, very low concentration of 
primary bile acids in bile, and by the finding of biallelic ABCB11 mutations (Table 1). Immune 
suppression was induced with prednisone and cyclosporine. No major problems were recorded 
following LT and she had normal serum liver tests and liver ultrasonography. At age 13.5 (40 
months after LT) while decreasing immune suppression, she developed subicterus and pruritus. 
Serum liver tests were abnormal except for GGT activity (Table 2). When increasing the dose 
of corticosteroid and cyclosporine, pruritus and jaundice disappeared and serum liver tests 
normalized. No explanation was found to this episode of normal GGT cholestasis. At age 24 
(15 years after LT), she gave birth to a normal male newborn. During a new pregnancy in 2007, 
at age 26, immune suppression was reduced. Pregnancy was complicated from the 6
th
 month by 
normal GGT cholestasis with severe pruritus and jaundice. Liver ultrasonography was normal. 
She was treated with ursodeoxycholic acid and cholestyramine without any improvement and 
she underwent a premature delivery by caesarean section giving birth to a female newborn with 
intrauterine growth retardation. After delivery, the patient underwent a liver biopsy that showed 
lobular cholestasis with diffuse giant cell transformation of hepatocytes and absence of signs of 
rejection or of biliary obstruction (Figure 1C). Cyclosporine and prednisone doses were 
increased, but cholestasis worsened. In the meantime her newborn baby developed intrahepatic 
cholestasis characterized by normal GGT serum activity, that spontaneously disappeared at age 
4 months. The patient was listed for a second LT. Intravenous immunoglobulins (1 g/kg) 
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produced a transitory reduction of total bilirubin and total serum bile acids (Table 3). 
Moreover, she developed melanonychia of hands and feet (Figure 2). An atrial fibrillation was 
documented after a malaise and she died because of a cardiac arrest six hours after admission to 
the hospital. 
Patient 2: Born from consanguineous parents, this baby boy developed hepatocellular 
cholestasis at age 1 month, characterized by persistent serum normal GGT activity and by 
numerous giant hepatocytes (Figure 1A). Unremitting pruritus, cirrhosis, and severe growth 
failure developed. PFIC2 diagnosis was made on the basis of negative BSEP canalicular 
immunostaining and on the presence of biallelic ABCB11 mutations (Figure 1B, Table 1). LT 
was performed at age 2.8 years with cyclosporine and prednisone regimen. A rejection 
developed at 3 weeks post-LT and was successfully treated with steroid boluses. An acute 
episode of normal GGT cholestasis with severe pruritus, discoloration of stools and subicterus, 
occurred 4.8 years after LT, while immune suppression was decreased (Table 2). Liver 
ultrasonography was normal. Liver biopsy showed canalicular cholestasis and giant 
hepatocytes, with slight centrilobular fibrosis, and absence of signs of rejection or of biliary 
obstruction. Immune suppression was increased, adding azathioprine, and cholestasis resolved 
(Table 2) without explanation. Ten years post-LT, systematic liver histology showed the 
persistence of numerous giant hepatocytes (Figure 1H). Prednisone was stopped 17 years after 
LT.  At age 22, the patient is alive with normal growth and sexual maturation; receiving 
azathioprine (1 mg/kg/d) and cyclosporine (1.5 mg/kg/d). Serum liver tests and renal function 
are normal. Cholestasis did not recur. The patient developed an atrial fibrillation of unknown 
cause (Table 3). 
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Methods 
ABCB11 sequence analysis 
Sequence analysis was performed as previously described [2]. In brief, DNA was extracted from 
EDTA blood (QIAampDNA Mini kit, Qiagen, Courtaboeuf, France). Mutation screening was 
done using PCR amplification and DNA sequencing of coding exons 2 to 28 and all splice 
junctions of ABCB11 (RefSeq NM_003742.2). 
Liver immunohistochemistry and bile analysis 
Native and post-transplant liver samples obtained during cholestatic episodes were studied in 
both patients. A polyclonal anti-BSEP and a monoclonal anti-MDR3 (Sigma-Aldrich) antibodies 
were used as described on paraffin-embedded sections [2,3,8]. Biliary concentration of bile acids 
was measured using standard procedures [2]. 
Immunofluorescence analysis 
Post-transplant serum samples from the two patients obtained during cholestatic episodes were 
screened at dilutions ranging from undiluted to 1:500 with the use of sections of normal human 
liver. For the shown experiments, sera of patients were used undiluted and at 1:25. Bound 
antibodies were detected using fluorescein isothiocyanate conjugated antihuman IgG, IgA and 
IgM antibodies (DakoCytomation). Sera from two patients transplanted for biliary atresia and 
obtained 10 years after LT were used similarly, and served as controls. 
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Results 
Post-LT liver immunohistochemistry and immunofluorescence analyses 
Canalicular BSEP immunostaining was negative in patient 1, 17.3 years post-LT and during a 
bout of normal GGT cholestasis (Figure 1D). In patient 2, 4.8 years post LT and during a bout of 
normal GGT cholestasis, canalicular BSEP immunostaining was faintly positive (Figure 1E). In 
both patients, canalicular MDR3 immunostaining used as a control was positive. 
Immunofluorescence staining of normal human liver sections incubated with serum of each 
patient collected at time of cholestasis bout, revealed, using an anti-human IgG antibody, clear 
staining of bile canaliculi (Figure 1F and G). No staining was seen when using an anti-human 
IgA or IgM antibody. When normal liver sections were incubated with serum of each control 
patient, no canalicular staining was seen using an anti-human IgG, IgA or IgM antibody (Figure 
1F). 
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Discussion 
PFIC2 is a common indication for pediatric liver transplantation. This procedure is thought to 
cure the genetic disease and recurrent disease related to immunization of the recipient against 
donor BSEP protein, has, until very recently, not been considered [1,2,5-7]. This study reports 
the clinical course and the long term evolution of 2 patients, successfully transplanted for PFIC2, 
and who developed after LT, episodes of normal GGT cholestasis with features suggesting 
recurrence of BSEP dysfunction. In our experience, this event developed in about 10 % of PFIC2 
transplanted patients [2]. Our report reinforces the idea that recurrence of BSEP dysfunction 
after LT, secondary to an allo-immunization process in a patient immunogically naive for BSEP, 
may represent a novel clinico-pathological entity more than a rare and sporadic phenomenon. 
The chronology of this condition is variable with a wide range of time between liver 
transplantation and the development of cholestasis. Also, the severity spectrum ranges from mild 
cases that can be reversed by increasing the dose of immunosuppression as in patient 2 and as in 
the patients reported by Jara et al [7], to episodes with very limited or no response to medical 
therapy, requiring retransplantation, as in patient 1 and in the patient reported by Keitel et al [6]. 
This also suggests that allo-immune induced BSEP dysfunction may remain undiagnosed in the 
post-transplant course because of its rapid resolution by simply increasing immunosuppression 
regimen. 
In the four previously reported patients, the presence of anti-BSEP IgG antibody, suggested an 
allo-immune reaction of the recipient directed against the BSEP protein of the donor liver [6,7]. 
It is assumed that these IgG allo-antibodies are internalized by hepatocytes, transported through 
the cell and reach the canaliculus membrane where they exert their blocking effect on BSEP 
[7,9-11]. The mechanisms that lead to allo-immune reaction are not precisely known and one can 
only hypothesize. Allo-immune reaction implies a loss of tolerance by the host of the graft 
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toward a wild type BSEP [6,7,12]. This may occur if an antigenic part of BSEP is exposed to 
blood lymphocytes [13]. Several circumstances in the post-transplant course might lead to 
abnormal exposure of BSEP to blood, such as hepatocyte necrosis due to infection or rejection, 
BSEP misrouting to the basal membrane of the hepatocytes, or regurgitation from bile to blood 
through increased paracellular permeability due to biliary obstruction [6,14]. Whether pregnancy 
may play a role in the loss of tolerance is not known. So far, nearly all PFIC2 patients in whom 
BSEP immunostaining was performed, including the patients reported here, showed no 
canalicular BSEP in native liver [2-4]. It is likely that in some cases (i.e. premature stop codon), 
BSEP is not expressed at all, and this would explain the lack of tolerance and the development of 
BSEP-reactive antibodies following LT. In other instances (i.e. missense mutation), BSEP may 
be retained in the endoplasmic reticulum, and peptides resulting from its degradation might be 
presented to immune cells and induce tolerance [15]. This might explain why not all PFIC2 
patients are affected by disease recurrence after LT. In both our patients, no or few protein 
expression in their native livers was expected, considering their genotypes [2,3,6,15]. Conditions 
favoring or triggering allo-immunization in patients transplanted for PFIC2 are unknown, but in 
our two patients as well as in two of the previously reported patients, reduction of 
immunosuppression was noted [7]. 
In both our patients, sera collected during the cholestatic episodes were tested against normal 
human liver tissue by immunofluorescence, and revealed an IgG specific canalicular reactivity. 
This suggests the presence of an antibody of IgG class specifically reacting against an epitope in 
bile canaliculus of normal liver [6,7]. In addition, canalicular BSEP immunostaining in the 
transplanted liver of each patient, using the anti-BSEP antibody, was negative or faint. This can 
likely be due to the presence of allo-anti BSEP IgG antibodies produced by the patient, that mask 
totally or partially the BSEP epitope recognized by the anti-BSEP antibody. Moreover, the 
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clinical and biochemical picture of a normal GGT cholestasis associated with features akin to 
PFIC2, and the absence of histological evidence of the most common causes of cholestasis in 
liver transplanted patients, such as rejection or biliary complications, strongly support an allo-
immune induced BSEP dysfunction in our patients.
 
The presence of associated extra hepatic 
autoimmune phenomena, not yet reported in the previously described patients with this 
condition, further supports the immune mediated nature of this entity. Indeed, atrial fibrillation 
may be caused by an immune mediated mechanism [16], and melanonychia is known to be 
associated with immune mediated disorders [17]. Interestingly, the newborn born from patient 1 
developed an early normal GGT cholestasis that spontaneously resolved at age 4 months. It has 
been shown that an ABCB11 heterozygous status represents a predisposition to develop transient 
neonatal cholestasis, characterized by slightly elevated serum GGT activity [18]. In this baby, 
likely harbouring an ABCB11 mutated allele transmitted from his mother, transplacental transfer 
of anti-BSEP antibodies might have led to transient blockage of the function of the wild type 
BSEP encoded by the normal allele, and favored transient neonatal cholestasis with normal 
serum GGT activity. 
These data confirm that allo-immune BSEP dysfunction may occur after liver transplantation in 
PFIC2 patients naive for BSEP. It may develop with symptomatic cholestasis even many years 
after an apparently well controlled transplantation. Allo-antibodies generated against BSEP of 
donor liver may inhibit BSEP function and cause cholestasis with PFIC2 like phenotype. It may 
be treatable or not by increasing immunosuppression and can lead to graft failure requiring 
retransplantation. It may also be associated with extrahepatic features and/or offspring transient 
neonatal normal GGT cholestasis of possible immune mediated mechanisms. Liver transplanted 
PFIC2 patients should be carefully monitored for appearance of anti-BSEP antibodies. 
Immunosuppression increase before normal GGT cholestasis onset might avoid insidious 
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progression of fibrosis in the liver graft. Prospective strategies should be thought to prevent 
“disease recurrence” in high-risk patients. 
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Legend to figures 
Figure 1. Initial and/or post-transplantation liver histology in patients 1 and 2, liver 
transplanted for PFIC2 (A, B, E, G, and H: patient 2. C, D, and F: patient 1). A: Native 
liver histology showing numerous giant hepatocytes (star), and canalicular cholestasis (arrow), 
inflammation and septal fibrosis. B: Negative immunohistochemical detection of canalicular 
BSEP in native liver. Note positive canalicular MDR3 immunostaining (Inset). C: Liver 
histology 17.3 years post-transplantation showing numerous giant hepatocytes (star) and 
canalicular cholestasis (arrow). D: Negative immunohistochemical detection of canalicular 
BSEP 17.3 years post-transplantation. Note positive canalicular MDR3 immunostaining (Inset). 
E: Faint immunohistochemical detection of canalicular BSEP 4.8 years post-transplantation. 
Note positive canalicular MDR3 immunostaining (Inset). F: Patient 1 serum collected 17.3 years 
post-transplantation was used for immunofluorescent staining of normal human liver. Antibodies 
within the serum sample (dilution, 1:25) were detected by an anti-human IgG antibody (lower 
part). Serum contained antibodies reactive to a canalicular epitope. A serum (undiluted) collected 
in a liver transplanted patient for biliary atresia 10 years post-transplantation was used as control 
and was not reactive to canaliculus (upper part). G: Patient 2 serum (1:25) collected 4.8 years 
post-transplantation was used for immunofluorescent staining of normal human liver as indicated 
in F. Serum contained antibodies reactive to a canalicular epitope. A serum collected in a second 
liver transplanted patient for biliary atresia 10 years post-transplantation was used as control 
(undiluted) and was not reactive to canaliculus (data not shown). H: Sirius red (upper part) and 
trichrome (lower part) stains 10 years post-transplantation showing thin septal, perisinusoidal 
and centrilobular fibrosis and numerous giant hepatocytes (star). 
Figure 2. Melanonychia involving nails of hands and feet that developed in patient 1 after 
liver transplantation. 
 B 
C 
F 
G H 
E 
A 
D 
Figure
Figure
Table 1. Characteristics at liver transplantation of the two patients with recurrent normal GGT cholestasis 
Patient 
Gender 
ABCB11 
mutations 
Canalicular 
BSEP staining 
 
Biliary bile 
acids 
(N>10 mmol/L) 
Age at LT 
 
Indication 
Native liver 
histology 
Serum liver tests at LT 
PT 
(N>70%) 
Total bilirubin 
(N<17µmol/L) 
ALT 
(N<40 IU/L) 
AFP GGT 
(N<60 IU/L) 
Patient 1 
 
Female 
Compound 
heterozygous 
p.Q101DfsX8 
and 
p.G982R with 
p.V444A 
Negative 
 
0.1 mmol/L 
9 years 
 
SC 
P 
Growth 
failure 
Cirrhosis 
Hepatocellular 
cholestasis 
Giant 
hepatocytes 
Portal 
inflammation 
100 36 234 N 17 
Patient 2 
 
Male 
Homozygous 
c.77-19T>A 
leading to 
abnormal 
splicing 
 
Homozygous 
p.V444A 
 
Negative 
 
NA 
2.8 years 
 
SC 
P 
Growth 
failure 
Cirrhosis 
Hepatocellular 
cholestasis 
Giant 
hepatocytes 
 
76 139 420 2 x N 20 
SC, severe cholestasis; P, pruritus refractory to medical management; PT, prothrombin time; ALT, alanine aminotransferase; AFP; alpha 
fetoprotein; GGT, gamma-glutamyl transpeptidase; BSEP, bile salt export pump, LT, liver transplantation; NA, not available. 
 
 
 
 
 
 
 
 
Table
Table 2. Clinical course of the two patients with recurrent normal GGT cholestasis after deceased liver transplantation 
Patient 
 
IS at 
cholestasis 
attack 
Circumstances and time to onset of 
normal GGT cholestasis*, post-LT: 
Serum liver tests during cholestatic flare 
Pruritus Liver biopsy PT 
(N>70%) 
Total bilirubin 
(N<17µmol/L) 
ALT 
(N<40IU/L) 
GGT 
(N<60 IU/L) 
Bile acids 
(N<15 µmol/L) 
Patient 1 
 
Cyclosporine 
(blood 
through 
levels: 
70-100 
ng/ml) and 
prednisone 5 
mg every 
other day 
 
13.5 years. 
Decrease of IS 
 
 
 
17 years, 
during the 6
th
 
month of a 2
nd
 
pregnancy. 
Decrease of IS 
during pregnancy 
Not performed 
 
 
 
 
 
17.3 years, after 
delivery 
90 
 
 
 
 
 
85 
          32 
 
 
 
 
 
620 
160 
 
 
 
 
 
600 
35 
 
 
 
 
 
45 
107 
 
 
 
 
 
352 
Patient 2 
 
Cyclosporine 
(blood 
through 
levels: 
200-250 
ng/ml) and 
prednisone 5 
mg every 
other day 
 
4.8 years 
Decrease of IS 
4.8 years 100 32 31 14 298 
IS, immunosuppression regimen; PT, prothrombin time; ALT, alanine aminotransferase; GGT, gamma-glutamyl tranpeptidase; LT, liver 
transplantation; *, cholestasis without rejection, infection, or biliary or vascular complications; NA, not available. 
 
Table 3. Evolution after recurrence of normal GGT cholestasis* on liver graft 
Patient Adaptation of IS Serum liver tests Symptoms Last follow-up 
PT 
(N>70%) 
Total bilirubin 
(N<17µmol/L) 
Bile acids 
(N<15µmol/L) 
Patient 1 Increase of 
cyclosporine dose 
and daily 
prednisone 
 
Intravenous 
immunoglobulins 
 
93 513 150 Unremitting P 
SC 
Hard hepatomegaly 
Hyperkeratosis of 
hands and feets 
Melanonychia 
 
At age 28 years: 
SC with persistence of abnormal 
liver tests 
Abrupt malaise 
Atrial fibrillation. Cardiac arrest 
and death, while awaiting for a 2
nd
 
LT 
Offspring: 
Transient neonatal cholestasis with 
normal serum GGT and 
spontaneous resolution at age 4 
months 
 
Patient 2 Increase of 
cyclosporine dose 
and daily 
prednisone 
 
Azathioprine 
started 
 
100 12 5 Disappearance of 
pruritus without 
recurrence 
 
Ten years post-LT: 
 Liver histology: no rejection 
but slight portal and lobular 
fibrosis with giant 
hepatocytes 
 Unexplained polyclonal 
hyper gamma-globulinemia 
(18.5 g/L) 
 Non organ specific 
autoantibodies: negative 
 
Alive at age 22 years with normal 
clinical exam and serum liver tests 
Atrial fibrillation of unknown cause 
 
IS, immunosuppression regimen; PT, prothrombin time; GGT, gamma-glutamyl transferase; LT, liver transplantation; *, cholestasis without 
rejection, infection, or biliary or vascular complications; SC, severe cholestasis; P, pruritus refractory to medical management. 
